Generic Name and Formulations:
Fentanyl (as citrate) 100mcg, 200mcg, 400mcg, 600mcg, 800mcg; buccal tabs.
Indications for FENTORA:
Breakthrough pain, in opioid-tolerant patients already receiving and who are tolerant to continuous opioid therapy for underlying persistent cancer pain. Opioid-tolerant patients are those taking oral morphine ≥60mg/day, transdermal fentanyl ≥25mcg/hr, oral oxycodone ≥30mg/day, oral hydromorphone ≥8mg/day, oral oxymorphone ≥25mg/day, oral hydrocodone ≥60mg/day, or equianalgesic dose of another opioid for ≥1 week.
Do not substitute with other fentanyl products; not equivalent to other fentanyl products on a mcg to mcg basis. Use lowest effective dose for shortest duration. ≥18yrs: Place tablet in buccal cavity (above a rear molar, between upper cheek and gum). Do not swallow whole, split, suck, or chew. Individualize. Initially 100mcg/dose; if pain unrelieved after 30mins, take only 1 additional dose; max 2 doses per episode. Must wait at least 4hrs before treating another episode. Reevaluate maintenance pain therapy if >4 doses/24hrs is needed. Conversion from Actiq: see full labeling. Concomitant use or discontinuation of CYP3A4 inhibitors or inducers: monitor closely and consider dose adjustments (see full labeling).
<18yrs: not established.
Opioid non-tolerant patients. Significant respiratory depression. Acute or post-op pain (including headache/migraine, dental pain, or ER). Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment. Known or suspected GI obstruction, including paralytic ileus.
Addiction, abuse, and misuse. Life-threatening respiratory depression. Accidental ingestion. Risks from concomitant use with benzodiazepines or other CNS depressants. Risk of medication errors. REMS enrollment required. Neonatal opioid withdrawal syndrome.
Life-threatening respiratory depression; monitor within first 24–72hrs of initiating therapy and following dose increases. Accidental exposure may cause fatal overdose (esp. in children). COPD, cor pulmonale, decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression; monitor and consider non-opioid analgesics. Abuse potential (monitor). Adrenal insufficiency. Head injury. Increased intracranial pressure, brain tumors; monitor. Seizure disorders. CNS depression. Impaired consciousness, coma, shock; avoid. Biliary tract disease. Acute pancreatitis. Bradyarrhythmias. Drug abusers. Renal or hepatic impairment. Reevaluate periodically. Avoid abrupt cessation. Elderly. Cachectic. Debilitated. Pregnancy; potential neonatal opioid withdrawal syndrome during prolonged use. Labor & delivery, nursing mothers: not recommended.
Increased risk of hypotension, respiratory depression, sedation with benzodiazepines or other CNS depressants (eg, non-benzodiazepine sedatives/hypnotics, anxiolytics, general anesthetics, phenothiazines, tranquilizers, muscle relaxants, antipsychotics, alcohol, other opioids); reserve concomitant use in those for whom alternative options are inadequate; limit dosages/durations to minimum required; monitor. During or within 14 days of MAOIs: not recommended. Risk of serotonin syndrome with serotonergic drugs (eg, SSRIs, SNRIs, TCAs, triptans, 5-HT3 antagonists, mirtazapine, trazodone, tramadol, MAOIs, linezolid, IV methylene blue); monitor and discontinue if suspected. Avoid concomitant mixed agonist/antagonist opioids (eg, butorphanol, nalbuphine, pentazocine) or partial agonist (eg, buprenorphine); may reduce effects and precipitate withdrawal symptoms. Potentiated by CYP3A4 inhibitors (eg, macrolides, azole antifungals, protease inhibitors, grapefruit juice). Antagonized by CYP3A4 inducers (eg, rifampin, carbamazepine, phenytoin). May antagonize diuretics; monitor. Paralytic ileus may occur with anticholinergics.
Nausea, dizziness, vomiting, fatigue, anemia, constipation, peripheral edema, asthenia, dehydration, headache; respiratory depression, severe hypotension, syncope, local reactions.
Available by restricted distribution program. Call (866) 822-1483 or visit www.tirfremsaccess.com to enroll. Caution patients and caregivers in proper handling and disposal; may be fatal to children.
Tabs—28 (4 tabs x 7 cards)
Sign Up for Free e-newsletters
- Steering Patients Toward Reliable Internet Resources
- Conception, Pregnancy Possible During TKI Therapy for Chronic Myeloid Leukemia
- Postremission Survival Influenced by Choice of Induction Therapy in AML
- Alternative Medicine Beliefs: How Far Will Cancer Patients Go for Alternative Results?
- Many Americans Unaware of the Promise of Personalized Medicine
- Proscription on Antiperspirant Use During Radiotherapy: Does the Advice Still Apply?
- Smartphone App Improves Management of Cancer-Related Pain, Anxiety
- Steering Patients Toward Reliable Internet Resources
- Lung Cancer-Specific Distress Screening Tool Not Needed But Has Potential Benefit
- Prophylaxis Improves Postchemotherapy Nausea/Vomiting Frequency, Hospitalizations
- How Culturally Competent Care Is Different for Jewish Women With Breast Cancer
- Incidence of Adverse Effects of Highly Emetogenic Chemotherapy in Breast Cancer
- Mechanical Shoulder Integrity Not Compromised After Breast-Conserving Surgery, Radiotherapy
- Allogeneic BCMA-Directed CAR-T in Multiple Myeloma: Slated to Hit Phase 1 in 2019
- Early Findings Indicate P-BCMA-101 May Be Effective, Tolerable in R/R Multiple Myeloma
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|